Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Options:
1) all the major grocery chains in my area allow on-line orders for pickup in the parking lot. Minimal cost. Even BevMo (haha)
2) get from restaurants. They supply chain is still packaging for restaurants (will take a while to switch over), so some are willing to sell.
3) small/local grocery chains still fairly empty and often w more product. So little risk. And lots more product.
Sure. But Taiwan, Singapore and S Korea also implemented a lot of other measures. Eg hard core tracing. Japan essentially did very little. So their low doubling rate is ‘odd’.
Masks:
Nature just published an article where, shockingly, they actually looked for expelled virus in people infected with different diseases, mask vs no mask. Who knew you could actually design a trial to look at this.
https://www.nature.com/articles/s41591-020-0843-2
Also see video of mask vs no mask:
https://www.bing.com/videos/search?q=lavision+mask+video&view=detail&mid=18ADA92398C0F817BA0418ADA92398C0F817BA04&FORM=VIRE
Freudian slip - I guess?
HCQ and Chloroquine MOA. The below linked paper (found by biomaven) is easily the best putative chloroquine MOA paper. The authors went out of their way to duplicate the results using a very different ‘drug’ but with same MOA. And then ruled out various other ways in which the pair of drugs could have the observed effect.
Note: quinine, like the two drugs used in the paper, is also a lysosomotropic agent.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/
From a pure death rate perspective what matters is the area under the curve. Even visually Philly clearly had more area under the curve (ie more deaths per 100,000), and the numbers in the story say the same (as they should since that’s a big difference in AOC).
And if the argument is economic, as I said, there are similar studies that showed big advantages to cities that went with a lockdown. So it’s a win/win. And this is not new. Similar lessons have been learned through centuries when epidemics were much more common (somewhat strangely I just saw a poem from 100 years ago about this)
I am mystified - your cite is explicit that lockdown saved lives.
HCQ for early hospitalization
Best HCQ trial yet. In earlier, less severe disease (where antivirals stand a much stronger chance of success)
https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1
Note: posting this before spending the necessary time to *fully* vet, so undoubtedly I will critique later.
More data is a poor substitute for good data. Sounds like a slogan, but it is mathematically true when dealing with unknown confounders (and human tendency to see what they want).
RVNC Agree it will have overwhelming efficacy. At start. And I have no doubt that they can get approval in the indication using the data. But the ability to penetrate the market is dependent on better initial efficacy and/or better duration. And for both of those I’d suggest the signal likely will be harder to see now.
That said, they might well be able to work w FDA before unblinding to get some pre-agreed rules. Assuming the FDA is even returning calls right now. And if they aren’t returning calls, at least Revance should have a plan.